News
Public · Published
Stifel maintains Hinge Health at Buy, raises price target to $135 from $130
Stifel kept its Buy rating on Hinge Health and raised its price target to $135 from $130, a 3.8% increase. That target implies 16.9% upside from the November 2 close of $115.48.
Published:
Updated:
What happened
Stifel kept its Buy rating on Hinge Health and raised its price target to $135 from $130, a 3.8% increase. That target implies 16.9% upside from the November 2 close of $115.48.
Confirmed
Global impact / market context
A higher price target signals an analyst expects more upside, which can draw investor attention to the stock. For a beginner, it means one research firm sees the shares worth more than before, though a target is an estimate, not a promise.
Analyst inference
Recent analyst targets on Hinge Health range from $110 to $140, with several firms keeping Buy or Overweight ratings, which means they lean positive. That clustered range shows mostly supportive views but disagreement about how much upside remains.
Analyst inference
What to watch
- Stifel's $135 target sits above the $115.48 November 2 close, so watch whether the share price moves toward that level. Confirmed
- Watch whether other analysts raise or cut their own Hinge Health targets, since changes could shift the current $110 to $140 range. Proposed
- Watch the company's next financial results for signs that revenue and costs support the expected upside, because targets rest on future profit estimates. Analyst inference
Evidence
- Original source link unavailable